Connect your AI

AnaptysBio, Inc. ANAB Price / book

Price / book at other companies

Bristol-Myers SquibbBMY

6.2×-1.0×

Eli LillyLLY

26.3×-20.7×

PfizerPFE

1.8×+0.2×

AmgenAMGN

20.6×-6.3×

Regeneron PharmaceuticalsREGN

2.6×+0.2×

BiogenBIIB

1.4×+0.3×

Other financials

Income statement

Revenue$25.6M-8.0%

Operating income-$34.6M-25.8%

Net income-$52.9M-34.5%

EPS (diluted)-$1.84-43.8%

Balance sheet

Cash & equivalents$248.5M+152%

Total debt$13.6K-99.9%

Total equity$12.7M-62.5%

Total assets$329.7M-21.9%

Cash flow

Operating cash flow-$25.9M-142%

CapEx$17.0K-51.4%

Free cash flow-$25.9M-142%

Valuation

Market cap$1.73B+180%

Enterprise value$1.48B+176%

P/S7.4×+1.9×

Profitability

Operating margin17.6%+9.6pp

Net margin-49.9%-22.6pp

FCF margin1.9%+1.0pp

Returns & leverage

Return on equity-343.8%-1,012pp

Debt / equity0×-0.5×

Current ratio7.6×-0.7×

Where this comes from

Calculated from AnaptysBio, Inc.’s reported figures.

market cap/total stockholders equity=125.1×

Based on the most recent quarter.

The official record: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about AnaptysBio, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is AnaptysBio, Inc.'s price / book?: AnaptysBio, Inc. (ANAB) reported price / book of 125.1× in Q1 2026.
How has AnaptysBio, Inc.'s price / book changed year-over-year?: AnaptysBio, Inc.'s price / book increased by 646.4% year-over-year, from 16.8× to 125.1×.
What is the long-term trend for AnaptysBio, Inc.'s price / book?: Over 5 years (2020 to 2025), AnaptysBio, Inc.'s price / book has grown at a 88.9% compound annual growth rate (CAGR), from 1.5× to 36.1×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.